Clinical Trial Testing the efficacy and Safety of Two Ramucirumab Doses Given as Second Line Treatment to Patients with Stomach Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-005067-32

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Evaluate the efficacy of ramucirumab 12 mg/kg versus placebo, both in combination with paclitaxel, in terms of PFS


Critère d'inclusion

  • Second-Line Metastatic or Locally Advanced, Unresectable
  • Gastric or Gastroesophageal Junction Adenocarcinoma